A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...

Opens in a new tab or window An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 ...

In those with grade 3 cervical intraepithelial neoplasia (CIN3), cells are already on the path toward malignancy. If left untreated, approximately one-third of these cases progress to cervical ...

achieved its primary endpoint in participants with cervical high-grade squamous intraepithelial lesions (HSIL). HSIL are precancerous lesions linked to human papillomavirus (HPV) that can lead to ...